Piper Sandler analyst David Amsellem lowered the firm’s price target on Collegium Pharmaceutical (COLL) to $36 from $37 and keeps a Neutral rating on the shares ahead of quarterly results. On the whole, the firm continues to take a constructive view of biopharma despite well-documented macro uncertainties.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on COLL:
- Collegium Pharmaceutical upgraded to Buy from Hold at Needham
- Drugmakers Raise the Prices on 583 Products to Start 2025
- Exxon and Shell cautious on Q4, Flutter cuts guidance: Morning Buzz
- Collegium Pharmaceutical Unveils 2025 Financial Projections
- Collegium Pharmaceutical sees FY25 revenue $735M-$750M, consensus $739.84M